Poolbeg Pharma (LON:POLB – Get Free Report) issued its earnings results on Tuesday. The company reported GBX (0.28) earnings per share for the quarter, Digital Look Earnings reports.
Poolbeg Pharma Stock Performance
POLB stock opened at GBX 7.38 on Thursday. The stock’s 50 day moving average price is GBX 8.07 and its 200 day moving average price is GBX 6.46. The firm has a market cap of £56.33 million, a P/E ratio of -7.85 and a beta of 1.83. Poolbeg Pharma has a 1 year low of GBX 3.30 and a 1 year high of GBX 9.30.
Wall Street Analyst Weigh In
Separately, Shore Capital Group restated a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday, September 24th.
About Poolbeg Pharma
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.
See Also
- Five stocks we like better than Poolbeg Pharma
- Boeing’s Fighter Victory Opens the Door to Decades of Defense Revenue
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
